Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways
about
Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosisCurrent status of novel antifibrotic therapies in patients with chronic liver diseaseIncreased caffeine consumption is associated with reduced hepatic fibrosisCoffee: The magical bean for liver diseases.PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesisCaffeine, a drug for all seasons.Coffee: a panacea or snake oil for the liver?Nrf2 and Snail-1 in the prevention of experimental liver fibrosis by caffeine.Relationship of Caffeine with Adiponectin and Blood Sugar Levels in Subjects with and without Diabetes.Caffeine and rolipram affect Smad signalling and TGF-β1 stimulated CTGF and transgelin expression in lung epithelial cells.Association of coffee consumption with serum adiponectin, leptin, inflammation and metabolic markers in Japanese workers: a cross-sectional study.Downregulation of mPGES-1 Expression via EGR1 Plays an Important Role in Inhibition of Caffeine on PGE2 Synthesis of HBx(+) Hepatocytes.Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator.Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes.Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.Less Smad2 is good for you! A scientific update on coffee's liver benefits.Coffee and liver - long way to go.Molecular Bases Underlying the Hepatoprotective Effects of Coffee.Drinking coffee burns hepatic fat by inducing lipophagy coupled with mitochondrial β-oxidationPathophysiology of NASH: perspectives for a targeted treatment.PPAR modulation of kinase-linked receptor signaling in physiology and disease.Impact of coffee on liver diseases: a systematic review.Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis.A comprehensive overview of hepatoprotective natural compounds: mechanism of action and clinical perspectives.Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling.Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model.Aqueous Date Flesh or Pits Extract Attenuates Liver Fibrosis via Suppression of Hepatic Stellate Cell Activation and Reduction of Inflammatory Cytokines, Transforming Growth Factor- β 1 and Angiogenic Markers in Carbon Tetrachloride-Intoxicated RatsCoffee Consumption and Risk of Biliary Tract Cancers and Liver Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies.Coffee Drinking and Mortality in 10 European Countries: A Multinational Cohort Study.Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo.The Starbuck stops here: it's a Smad world.Autophagy mediated by endoplasmic reticulum stress enhances the caffeine-induced apoptosis of hepatic stellate cells.Coffee prevents CCl(4)-induced liver cirrhosis in the rat.Caffeine is protective in patients with non-alcoholic fatty liver disease.Caffeine intake decreases oxidative stress and inflammatory biomarkers in experimental liver diseases induced by thioacetamide: Biochemical and histological study.Simvastatin augments activation of liver regeneration through attenuating transforming growth factor-β1 induced-apoptosis in obstructive jaundice rats.Metabolic effects of physiological levels of caffeine in myotubes.Protective effects of baicalin on carbon tetrachloride induced liver injury by activating PPARγ and inhibiting TGFβ1.Oral application of 1,7-dimethylxanthine (paraxanthine) attenuates the formation of experimental cholestatic liver fibrosis.
P2860
Q21560965-AEC2092E-9E0A-4DA5-B666-DB82B2810BAEQ30473375-EB268B6C-3B26-4C15-91AA-0D41A70BED89Q33572385-2C25F973-AAED-4BE3-9652-A690F595F9DDQ33716189-BB824A2A-0C97-4BC0-BD37-C5315AF65688Q33745028-8FF66B9F-78D4-414E-8284-CDC14E2C34FCQ33938555-AC376D33-F105-41B8-8FE2-DE3DDCEC2E9CQ34079596-C6B56511-9EE5-43FC-A3BB-9513CFFCD4E6Q35079069-327EB329-1CD5-428F-A802-9DCC3430A3FAQ35139537-05DC6A91-0FEF-4A46-83E1-AEA75D02A8E1Q35168732-50336CD1-F321-467B-821D-489A246813F8Q35944954-53731F94-8D21-478B-9F46-636C911DCA78Q36204556-11711AF6-400F-4AFE-B624-1957BC48CFB4Q37326935-6FDC56FD-BC4F-4505-8F9D-26645B43998EQ37331302-4FC1F01F-DACB-4B1D-BF93-A699D7B6FC5DQ37373460-B843115F-2162-4ACE-BA5E-0B147109FD0AQ37440725-87703068-1CC6-482E-B952-F7DDAC405227Q37554158-BD5E4B83-C8D9-4992-B545-9430D78552D7Q37613528-E2A00384-95E8-403D-937F-F8EA89849685Q37628490-633E9A73-0960-47C2-AFA3-F00069183654Q37665985-B0B34FC1-1C4A-40D9-A56A-F00E89EBE00EQ37699476-EAF82806-8083-45DA-B82C-19AAC6799873Q37765370-CC8210A1-F60C-46E8-BFF6-34ABFAD8B207Q38150457-23D4FF36-57DC-4780-8277-215F302331AFQ38326327-D903DFE4-3630-4AD4-AFFD-74120F8524EAQ38588143-59FD9910-DBF7-4D55-9DD2-B21CF1498149Q38973928-9E0BF337-5605-45FD-9522-A0D405C4AF19Q39133812-3C74A01C-90AE-4017-A335-23DFFFA381E7Q39772568-A74F1698-A32D-4C06-8D45-DD5AE1CC5316Q40068043-7B37304F-79A9-4C19-981C-84CF503994F7Q40129062-DEA32E90-678F-4B97-B5B3-0C0E5FA9E2E7Q41833192-96087B37-0EA7-47C9-932D-F6505C710EFBQ42177842-4E86A370-A25B-470C-A2D4-E5B80D90BCA6Q42280211-F2A82AE7-7BCC-4B3B-92EA-77AE32679DEFQ45899263-FC3D631B-4374-4834-9736-69D8DE05A4E4Q46818665-A00E0821-3B01-4439-A380-EFB7F6030AA0Q46951957-15896079-B28C-49AD-932E-C3DDCC9BD088Q47334982-48479679-E82F-47E8-9453-536823D02CFBQ47338074-5F086EF1-C707-4691-B6F6-9F02A3ADCD98Q47370380-41F069F9-16AF-4239-9739-06B236AB5796Q50523966-A642F2A6-1E7A-4F97-AE3B-0C3E48CBCF38
P2860
Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways
description
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2008
@ast
im November 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2008/11/01)
@sk
vědecký článek publikovaný v roce 2008
@cs
wetenschappelijk artikel (gepubliceerd op 2008/11/01)
@nl
наукова стаття, опублікована в листопаді 2008
@uk
مقالة علمية (نشرت في نوفمبر 2008)
@ar
name
Pharmacological application of ...... and SMAD2/3-dependent pathways
@ast
Pharmacological application of ...... and SMAD2/3-dependent pathways
@en
Pharmacological application of ...... and SMAD2/3-dependent pathways
@nl
type
label
Pharmacological application of ...... and SMAD2/3-dependent pathways
@ast
Pharmacological application of ...... and SMAD2/3-dependent pathways
@en
Pharmacological application of ...... and SMAD2/3-dependent pathways
@nl
prefLabel
Pharmacological application of ...... and SMAD2/3-dependent pathways
@ast
Pharmacological application of ...... and SMAD2/3-dependent pathways
@en
Pharmacological application of ...... and SMAD2/3-dependent pathways
@nl
P2093
P921
P1476
Pharmacological application of ...... and SMAD2/3-dependent pathways
@en
P2093
Axel M. Gressner
Birgit Lahme
Katharina Rehbein
Monika Siluschek
Olav A. Gressner
P304
P356
10.1016/J.JHEP.2008.03.029
P577
2008-11-01T00:00:00Z